VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease (Articolo in rivista) (literal)

Anno

• 2008-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1111/j.1463-1326.2008.00943.x (literal)

Alternative label

• Freeby, M.; Goland, R.; Ichise, M.; Maffei, A.; Leibel, R.; Harris, P. (2008)
  VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease
  in Diabetes, obesity and metabolism (Print)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Freeby, M.; Goland, R.; Ichise, M.; Maffei, A.; Leibel, R.; Harris, P. (literal)

Pagina inizio

• 98 (literal)

Pagina fine

• 108 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 10 (literal)

Rivista

• Diabetes, obesity and metabolism (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

• 11 (literal)

Note

• ISI Web of Science (WOS) (literal)
• ISI Web of Science (WoS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Columbia University; Columbia University; Columbia University; Consiglio Nazionale delle Ricerche (CNR) (literal)

Titolo

• VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease (literal)

Abstract

• The common pathology underlying both type 1 and type 2 diabetes (T1DM and T2DM) is insufficient beta-cell mass (BCM) to meet metabolic demands. An important impediment to the more rapid evaluation of interventions for both T1DM and T2DM lack of biomarkers of pancreatic BCM. A reliable means of monitoring the mass and/or function of beta-cells would enable evaluation of the progression of diabetes as well as the monitoring of pharmacologic and other interventions. Recently, we identified a biomarker of BCM that is quantifiable by positron emission tomography (PET). PET is an imaging technique which allows for non-invasive measurements of radioligand uptake and clearance, is sensitive in the pico- to nanonnolar range and of which the results can be deconvoluted into measurements of receptor concentration. For BCM estimates, we have identified VMAT2 (vesicular monoamine transporter type 2) as a biomarker and [(11)C] DTBZ (dihydrotetrabenazine) as the transporter's ligand. VMAT2 is highly expressed in beta-cells of the human pancreas relative to other cells of the endocrine and exocrine pancreas. Thus measurements of [(11)C] DTBZ in the pancreas provide an indirect measurement of BCM. Here we summarize our ongoing efforts to validate the clinical utility of this non-invasive approach to real-time BCM measurements (literal)

Prodotto di

• Analisi cellulare e molecolare della risposta immunitaria indotta da vaccini sintetici (SV.P15.009.002) (Modulo)
• Istituto di genetica e biofisica \"Adriano Buzzati Traverso\" (IGB) (Istituto)

Autore CNR

• ANTONELLA MAFFEI (Persona)

Insieme di parole chiave

• Parole chiave di "VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease" (Insieme di parole chiave)

Incoming links:

Prodotto

• Istituto di genetica e biofisica \"Adriano Buzzati Traverso\" (IGB) (Istituto)
• Analisi cellulare e molecolare della risposta immunitaria indotta da vaccini sintetici (SV.P15.009.002) (Modulo)

Autore CNR di

• ANTONELLA MAFFEI (Persona)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Diabetes, obesity and metabolism (Rivista)

Insieme di parole chiave di

• Parole chiave di "VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease" (Insieme di parole chiave)